Top-Tier Central Lab Guanhe Medicine: Growing with the Chinese Market and Empowering High-Quality Innovation in Drug Development

Guanhe Medicine, a joint venture established by Dian Diagnostics and Tigermed in 2016, provides central laboratory services for clinical trials in accordance with the College of American Pathologists (CAP) quality system standards. To date, Guanhe Medicine has delivered rigorous and complex laboratory solutions for more than 300 Phase I–IV drug clinical trials. These solutions encompass study design, testing services, and associated central laboratory project management, laboratory supplies, specimen management and long-term storage, sample logistics, real-time online reporting, data analysis and transfer, and system integration.

Q1

China’s CRO industry is undergoing a period of rapid development. As a star central laboratory company in China in recent years, could you briefly introduce the pain points addressed by Guanhe Medicine and its core strengths?

General Manager Xu Yi: Guanhe Medicine is committed to providing the most valuable central laboratory services and solutions for new drug trials, helping clients unlock product value and ultimately achieve success in clinical trials. Our highly specialized clinical research team, with extensive experience in clinical studies, serves new drug development, reducing R&D costs for pharmaceutical companies while improving R&D efficiency.

During the most severe phase of the COVID-19 pandemic this February, we promptly deployed an elite team to engage in clinical research. Under the leadership of the scientific teams from Guanhe Pharma and Dian Diagnostics, project workflow planning was completed within just two days. Despite challenges such as traffic controls and shortages of supplies, we successfully procured essential experimental materials—including equipment, reagents, and consumables—in a timely manner, thereby firing the “first shot” in the “Battle of Hope” against the epidemic. This fully demonstrates Guanhe Pharma’s strong capabilities in professional expertise and resource integration.It's a Title

Q2

The continuous development of the industry has also driven the optimization of industrial structure and resource allocation, as well as the enhancement of service capabilities for central laboratory enterprises. So, what do you consider to be the core competitiveness of Guanhe Pharma?

General Manager Xu Yi: Guanhe Medicine has established strategic partnerships with international CRO central laboratories, including MLM Medical Laboratories in Europe, BARC, ICON, and Hematogenix. In 2019, we participated for the first time in the Proficiency Testing (PT) for Next-Generation Sequencing Solid Tumor (NGSST) organized by the College of American Pathologists (CAP) and passed the test with an excellent perfect score.

These achievements are attributable to Guanhe Pharma’s robust professional capabilities, its experienced management team, and years of accumulated expertise. Led by five PhDs with extensive clinical trial experience, our elite team has supported more than 300 complex clinical trials. Leveraging highly specialized global knowledge, regulatory guidance, and information systems, we deliver creative, enterprise-grade customized services for drug clinical development and post-marketing companion diagnostics through cutting-edge testing technologies, rigorous methodological validation, and efficient, rapid technology transfer. This approach maximizes testing efficiency and cost savings for innovative drug R&D, thereby accelerating project timelines.

Q3

The transformation and development of the Chinese market will also bring a series of development opportunities to enterprises. What are the opportunities that Guanhe Pharmaceutical should seize?

Xu Yi, General Manager: China boasts a vast population base, making it the world’s largest single consumer market and the market with the greatest growth potential. Meanwhile, continuous improvements and guidance in China’s pharmaceutical regulatory policies have gradually turned the country into the most dynamic and vibrant market for innovative drug R&D globally. Therefore, both traditional pharmaceutical companies and newly established firms in China will prioritize innovative drug R&D as a key strategic direction for their future development. As a company that has grown alongside the innovative drug R&D sector, Guanhe will leverage this trend to continuously enhance its service capabilities for pharmaceutical enterprises, thereby securing greater room for development amidst the surge in innovative drug research and development.

Q4

How do you plan to seize this opportunity and ride the momentum?

Q5

After settling into I‧Campus, which forms of support provided by the Wuxi government have you found most helpful?

It's a Title

Q6

Why Did You Decide to Join I‧Campus? How Does I‧Campus Help You Accelerate Business Expansion?

It's a Title

Q7

Could you share with us your company's primary needs at this stage?

It's a Title